文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

中性粒细胞与淋巴细胞比值和血小板与淋巴细胞比值早期动态变化对免疫检查点抑制剂治疗头颈部鳞状细胞癌疗效的预测价值。

Predictive value of early dynamic changes of NLR and PLR for the efficacy of immune checkpoint inhibitor in head and neck squamous cell carcinoma.

机构信息

Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea; Department of Translational Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.

Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.

出版信息

Oral Surg Oral Med Oral Pathol Oral Radiol. 2024 Dec;138(6):763-771. doi: 10.1016/j.oooo.2024.07.014. Epub 2024 Aug 10.


DOI:10.1016/j.oooo.2024.07.014
PMID:39181857
Abstract

OBJECTIVE: We analyzed the predictive value of dynamic changes in neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) in recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) treated with immune checkpoint inhibitors (ICIs). STUDY DESIGN: A total of 104 patients with R/M HNSCC treated with ICIs during August 2018 to June 2023 were included. Dynamic changes were defined as the difference between NLR and PLR on day 1 of cycles 1 and 2. RESULTS: Patients with increased NLR or PLR had an independently increased risk of disease progression at the first response evaluation (odds ratio [OR] 5.26, P = .005; OR 2.29, P = .042), disease progression (hazard ratio [HR] 2.29, P = .003; HR 1.68, P = .027), and death (HR 1.86, P = .027; HR 1.68, P = .037). Furthermore, patients with a decrease in NLR showed longer progression-free survival, with HRs of 0.36 (P < .001) for those with low pre-ICI NLR and 0.52 (P = .041) for those with high pre-ICI NLR, compared to those with increased NLR. CONCLUSIONS: Increased NLR or PLR was associated with adverse outcomes after ICI treatment in patients with R/M HNSCC.

摘要

目的:我们分析了中性粒细胞与淋巴细胞比值(NLR)和血小板与淋巴细胞比值(PLR)在接受免疫检查点抑制剂(ICI)治疗的复发性和/或转移性(R/M)头颈部鳞状细胞癌(HNSCC)患者中的预测价值。

研究设计:共纳入 104 例在 2018 年 8 月至 2023 年 6 月期间接受 ICI 治疗的 R/M HNSCC 患者。动态变化定义为第 1 周期和第 2 周期第 1 天 NLR 和 PLR 的差值。

结果:NLR 或 PLR 升高的患者在首次反应评估时疾病进展的风险独立增加(优势比 [OR] 5.26,P =.005;OR 2.29,P =.042)、疾病进展(风险比 [HR] 2.29,P =.003;HR 1.68,P =.027)和死亡(HR 1.86,P =.027;HR 1.68,P =.037)。此外,NLR 降低的患者具有更长的无进展生存期,低基线 NLR 的患者 HR 为 0.36(P <.001),高基线 NLR 的患者 HR 为 0.52(P =.041),与 NLR 升高的患者相比。

结论:在 R/M HNSCC 患者中,ICI 治疗后 NLR 或 PLR 增加与不良结局相关。

相似文献

[1]
Predictive value of early dynamic changes of NLR and PLR for the efficacy of immune checkpoint inhibitor in head and neck squamous cell carcinoma.

Oral Surg Oral Med Oral Pathol Oral Radiol. 2024-12

[2]
Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12.

Cancer Res Treat. 2021-7

[3]
Hypoalbuminemia and hypercalcemia are independently associated with poor treatment outcomes of anti-PD-1 immune checkpoint inhibitors in patients with recurrent or metastatic head and neck squamous cell carcinoma.

World J Surg Oncol. 2024-9-11

[4]
Potential of Nutritional Markers as Predictors After Immunotherapy in Advanced Head and Neck Squamous Cell Carcinoma.

Anticancer Res. 2024-9

[5]
Relation of baseline neutrophil-to-lymphocyte ratio to survival and toxicity in head and neck cancer patients treated with (chemo-) radiation.

Radiat Oncol. 2018-11-6

[6]
Systemic immune response in squamous cell carcinoma of the head and neck: a comparative concordance index analysis.

Eur Arch Otorhinolaryngol. 2019-7-16

[7]
Neutrophil-to-lymphocyte ratio as a prognostic marker for head and neck squamous cell carcinoma treated with immune checkpoint inhibitors: Meta-analysis.

Head Neck. 2022-5

[8]
Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis.

Int Immunopharmacol. 2020-8

[9]
Systemic inflammatory markers as independent prognosticators of head and neck squamous cell carcinoma.

Head Neck. 2015-1

[10]
Prognostic value of inflammatory markers NLR, PLR, and LMR in gastric cancer patients treated with immune checkpoint inhibitors: a meta-analysis and systematic review.

Front Immunol. 2024

引用本文的文献

[1]
Prognostic value of platelet to lymphocyte ratio (PLR) in breast cancer patients receiving neoadjuvant therapy: a systematic review and meta-analysis.

Front Immunol. 2025-8-20

[2]
Systemic Inflammatory Markers as Prognostic Factors in Oral Squamous Cell Carcinoma of the Tongue.

Biomedicines. 2025-3-20

[3]
Prognostic value of platelet-to-lymphocyte ratio in patients with oral squamous cell carcinoma: a systematic review and meta-analysis.

BMC Oral Health. 2024-10-22

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索